Page 59 - Read Online

Feun et al. Immunotherapy for hepatocellular carcinoma

Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, evidence and potential for improving overall survival. Clin Cancer
Carson WE 3rd. The Raf kinase inhibitor sorafenib inhibits JAK- Res 2012;18:3686-96.
STAT signal transduction in human immune cells. J Immunol 52. Zhu AX, Gold PJ, El-Koueiry AB, Abrams TA, Morikawa H,
2015;195:1995-2005. Ohtomo T, Philip PA. A phase I study of GC33, a recombinant
45. Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, Yang PC, Cheng humanized antibody against glypican-3, in patients with advanced
AL. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibtions hepatocellular carcinoma (HCC). J Clin Oncol 2011;29 suppl:abstr
of effector T cells in tumor environment to augment antitumor 4085.
immunity. Int J Cancer 2014;134:319-31. 53. Okusaka T, Ikeda M, Ohkawa S, Yamamoto S, Suzuki I, Furuse J. A
46. Chen J, Ji T, Zhao J, Li G, Zhang J, Jin R, Liu J, Liu X, Liang phase I study of GC33 in Japanese patients with advanced hepatocellular
X, Huang D, Xie A, Lin H, Cang Y, Cai X. Sorafenib-resistant carcinoma (HCC). J Clin Oncol 2013;31 suppl 4:abstr 235.
hepatocellular carcinoma stratified by phosphorylated ERK activates 54. Abou-Alfa GK, Yen CJ, Carrasquillo JA, Hsu CH, Gansukh B, Ma
PD-1 immune checkpoint. Oncotarget 2016;7:41274-84. J, Hollywood E, Wan PJ, Shao YY, Lin ZZ, Frenette C, O’Neil BH,
47. Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Schwartz LH, Ohtomo T, Tanaka T, Chen YC, Ukrainskyj S, Saltz
Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay D, Lafdil L, Lee RM, Cheng AL. Phase I b study of RO5137382/GC33 in
F, Pawlotsky JM. Programmed death ligand 1 expression in combination with sorafenib in patients with advanced hepatocellular
hepatocellular carcinoma: relationship with clinical and pathological carcinoma (HCC) (NCT00976170). J Clin Oncol 2014;32 suppl:abstr
features. Hepatology 2016;64:2038-46. 4100.
48. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, 55. Hashimoto K, Perera A, Ogita Y, Nakamura M, Ishiguro T, Sano Y,
Filmus J. Glypican-3: a novel serum and histochemical marker for Kinoshita Y, Sakurai MK, Frings W, Komatsu SI, Kaneko A, Ueda
hepatocellular carcinoma. Gastroenterology 2003;125:89-97. M, Kishishita S, Gianella-Borradori A. A phase I dose escalation
49. Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target and cohort expansion study of T-cell redirecting bispecific antibody
in hepatocellular carcinoma. FEBS J 2013;280:2471-6. against Glypican 3 in patients with advanced solid tumors. J Clin
50. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the Oncol 2016;34 suppl:abstr TPS2592.
growth of hepatocellular carcinoma by stimulating canonical Wnt 56. Donkor MK, Sarkar A, Li MO. TGF-β1 produced by activated
signaling. Cancer Res 2005;65:6245-54. CD4(+) T cells antagonized T cell surveillance of tumor development.
51. Sawada Y, Yoshikawa T, Nobucka D, Shirakawa H, Kuronuma T, Oncoimmunology 2012;1:162-71.
Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, 57. Song S, Yuan P, Wu H, Chen J, Fu J, Li P, Lu J, Wei W. Dendritic
Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse cells with an increased PD-L1 by TGF-β induce T cell anergy for the
J, Kinoshita T, Nakatsura T. Phase I trial of a glypican-3-derived cytotoxicity of hepatocellular carcinoma cells. Int Immunopharmacol
peptide vaccine for advanced hepatocellular carcinoma: immunologic 2014;20:117-23.

Hepatoma Research ¦ Volume 3 ¦ March 22, 2017 51